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apy additional administration of rhEPO might be consid-
ered. However, the mechanism for not responding to intra-
venous iron therapy despite iron deficiency anemia still 
remains unclear to a large extent. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Iron deficiency is the most common nutrient deficien-
cy in the world and the most common cause of anemia in 
pregnancy. According to the WHO’s World Health Re-
port 2002, as many as 4–5 billion people, or 66–80% of
the world’s population, may be iron deficient, while 2 bil-
lion – over 30% of the world’s population – are anemic, 
mainly due to iron deficiency  [1] .
 The prevalence of gestational iron deficiency is 10–
15% in industrial countries such as Switzerland, Germa-
ny, and the USA, rising to 50–75% in developing coun-
tries. But due to increasing migration the problem of iron 
deficiency anemia is to be rising in industrial countries.
 The daily iron requirement in pregnancy is 4–5 mg, a 
figure which cannot be met even by increased intestinal 
absorption from an optimal diet. In other words, iron bal-
ance is inevitably negative in every pregnancy, shown by 
the continuous decline in serum ferritin levels to term  [2] .
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 Abstract 
 Objective: To evaluate the effectiveness of a stepwise use of 
recombinant human erythropoietin (rhEPO) in pregnant pa-
tients with severe anemia or nonresponsive to intravenously 
administered iron only.  Methods: All subjects had iron defi-
ciency anemia, i.e., a hemoglobin (Hb) level  ! 10.0 g/dl and 
ferritin  ^  15   g/l. Patients with an Hb level  6 9.0 g/dl and 
 ! 10.0 g/dl received 200 mg iron sucrose intravenously twice 
weekly. If response to therapy was poor, patients addition-
ally received 10,000 U rhEPO twice weekly. Patients with an 
Hb level  ! 9.0 g/dl primarily received iron sucrose and rhEPO 
likewise.  Results: Of the 84 patients, 59 had a baseline Hb 
level between 9.0 and 9.9 g/dl, of whom 32 responded poor-
ly, thus receiving additional rhEPO. Twenty-five patients had 
a baseline Hb level  ! 9.0 g/dl. The overall Hb level after ther-
apy was 11.0 g/dl ( 8 0.5, range 10.0–12.6 g/dl). Mean duration 
of therapy was 3.5 weeks (7 infusions).  Conclusion: This 
study shows an effective treatment regimen for patients 
with various degrees of anemia in pregnancy. Iron sucrose is 
a safe and effective treatment option. In cases of severe iron 
deficiency anemia or poor response to parenteral iron ther-
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 This can result in iron store depletion, which has a 
qualitative and quantitative impact on maternal erythro-
poiesis with the possible appearance of anemia. Gesta-
tional anemia carries several risks for the mother and the 
fetus. Depending on its severity, the risk of preterm de-
livery and low birth weight is elevated  [3] . In the mother, 
in both pregnancy and the puerperium, when the prob-
lem is magnified by puerperal blood loss, iron deficien-
cy anemia impairs performance and induces tiredness, 
headaches and dizziness. The WHO has estimated that 
anemia contributes to 20% of all maternal deaths  [1] .
 Rapid and effective correction of anemia is thus a core 
target in obstetric management. As the efficacy of orally 
administered high-dose iron is limited by side effects and 
noncompliance, and blood transfusions are relegated to 
use as a final resort due to the risk of viral contamination 
and other potential complications  [4] , modern alternative 
strategies call for parenteral administration of well-toler-
ated iron preparations (e.g. iron sucrose).
 Iron sucrose alone or in combination with recombi-
nant human erythropoietin (rhEPO) has been success-
fully used in the treatment of anemia in pregnancy  [5–8] 
as well as in the puerperium  [9, 10] .
 We were able to demonstrate successful treatment of 
iron deficiency anemia in pregnancy with a combination 
of rhEPO and iron sucrose  [5] , but we are also aware of 
the mainly economic limitations of such a costly treat-
ment regimen. Therefore, we set up a study protocol to 
discriminate between patients who might be in need of a 
combined therapy compared to treatment with iron su-
crose alone. If anemia was more severe [hemoglobin (Hb) 
 ! 9.0 g/dl], we decided to treat these patients with the 
most efficient combination of iron sucrose and rhEPO 
from the beginning of therapy. With this approach our 
aim was to set up a stepwise therapy scheme for an effec-
tive and rapid treatment of iron deficiency requiring in-
travenous administration of iron (sucrose). Hb was cho-
sen as primary target as it is the most relevant for clini-
cians’ daily routine.
 Materials and Methods 
 The hospital’s institutional review board approved the study 
protocol. Patients gave informed consent before inclusion. Treat-
ment was not started before 16 weeks of gestation and was contin-
ued for 4 weeks (i.e., 8 infusions or a maximum iron dose of 1,600 
mg, according to calculated maximum iron deficit) or until the 
target Hb level of 11.0 g/dl was reached. Target Hb was chosen ac-
cording to the CDC cutoff for anemia in the 3rd trimester  [11] .
 Inclusion Criteria 
 Subjects had iron deficiency anemia, i.e., an Hb level  ! 10.0
g/dl and a ferritin level  ^  15   g/l. All patients had received oral 
iron supplements (80 mg iron sulfate daily) on a routine basis 
since the beginning of the second trimester, but developed ane-
mia. Minimum duration of oral iron supplementation was 4 
weeks, before intravenous therapy was commenced.
 Exclusion Criteria 
 Women with anemia from causes other than iron deficiency 
(e.g. infection, chronic bleeding or renal failure) or previous blood 
transfusions, with a history of hematologic disease (e.g. thalasse-
mia or sickle cell disease) or a history of iron or rhEPO intolerance 
were all excluded.
 Study Groups 
 All patients were recruited on a consecutive and prospective 
basis from our antenatal clinic. Patients with an Hb level between 
 6 9.0 g/dl and  ! 10.0 g/dl received 200 mg (10 ml) iron sucrose 
(Venofer  , Vifor International, St. Gallen, Switzerland) intrave-
nously twice weekly (group A). If response to therapy was poor 
(i.e., Hb increase  ! 0.7 g/dl) after 2 weeks (4 infusions), patients 
additionally received 10,000 U rhEPO (Eprex  , Janssen-Cilag, 
Baar, Switzerland) (group B).
 Patients with an Hb level  ! 9.0 g/dl received iron sucrose (Ve-
nofer) and rhEPO (Eprex) twice weekly from the start of therapy 
(group C).
 In all three groups therapy was continued for a maximum of 
4 weeks (or 8 infusions, as after 1,600 mg iron infused a further 
increase in Hb was not to be expected) or until the target Hb lev-
el of 11.0 g/dl was reached or until delivery.
 Drug Administration 
 After inserting a butterfly into the cubital vein, 200 mg iron 
sucrose, diluted in 100 ml 0.9% saline solution, were infused over 
10 min. The cannula was flushed again with 5 ml saline solution 
and if appropriate, rhEPO was then injected as a bolus (1 ml); in-
jection was again followed by a saline solution flush. Heart rate 
and blood pressure were monitored before and 10 min after ther-
apy.
 Laboratory Tests 
 Blood samples were taken twice weekly immediately before 
therapy (in ethylenediaminetetraacetic acid-treated tubes, Vacu-
tainer TM , Becton Dickinson, Plymouth, UK) for routine hemato-
logic examination, including platelet count, and once weekly (se-
rum samples) for determination of iron status [ferritin level, 
transferrin saturation, soluble transferrin receptor (sTfR), C-re-
active protein level to detect underlying infection, and endoge-
nous erythropoietin (eEPO) levels]. Hematologic parameters 
were determined using a flow cytometric hematology analyzer 
(Advia  120, Bayer Health Care, Leverkusen, Germany).
 Erythropoietin (EPO) level was measured by enzyme-linked 
immunosorbent assay (R&D Systems Europe, Abingdon, UK). 
For measuring serum ferritin, chemiluminometric sandwich im-
munoassay was performed using the Automated Chemilumines-
cence System (ACS) 180 (Chiron Diagnostics, East Walpole, 
Mass., USA). C-reactive protein (TinaQuant turbidimetric im-
munoassay, Roche Diagnostics, Rotkreuz, Switzerland) and se-
rum iron (FerroZine method, Hach, Loveland, Colo., USA) were 
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assayed using a Roche/Hitachi 747 (Roche Diagnostics, Engle-
wood, N.J., USA) workstation; transferrin saturation and sTfR 
concentration were measured by enzyme immunoassay based 
upon the double antibody sandwich method (Ramco Laborato-
ries, Houston, Tex., USA).
 Erythrocyte folate and vitamin B 12 (chemiluminometric sand-
wich immunoassay, Beckman Coulter, Fullerton, Calif., USA) 
were also assessed before the start of therapy.
 The ratio of sTfR and serum ferritin was calculated using the 
formula: sTfR at inclusion/log ferritin at inclusion.
 Statistics 
 For intergroup comparisons nonparametric ANOVA with 
post hoc Bonferroni/Dunn analysis was performed (SatView 
5.0.1, SAS Institute, Cary, N.C., USA). A significance level of 
 ! 0.05 was used in all tests. Data are given as mean  8 SD.
 Results 
 Eighty-four patients were included in this study. All 
patients were of Caucasian ethnicity. Fifty-nine patients 
(groups A and B) had a baseline Hb level between 9.0 and 
9.9 g/dl, of whom 32 women responded poorly to the ini-
tial therapy, receiving additional rhEPO injections after 
2 weeks of treatment. Twenty-five patients (group C) had 
a baseline Hb level below 9.0 g/dl. Baseline hematologic 
characteristics and iron parameters are given in  table 1 .
 The groups did not differ statistically significantly in 
age or time of treatment initiation. No patient had an ab-
normal C-reactive protein level. The groups did not differ 
in vitamin B 12 or erythrocyte folate levels. However, some 
patients showed levels below the normal range for non-
pregnant patients, but no macrocytosis or elevated per-
centage of macrocytics.
 Hematologic Response 
 The target Hb level was 11.0 g/dl for all three groups. 
Therapy was stopped after the target Hb level was reached 
or after a maximum iron dose of 1,600 mg. The overall 
Hb level after therapy was 11.0 g/dl ( 8 0.5, range 10.0–
12.6 g/dl). Thirty-one patients had an Hb level between 
10.0 and 10.9 g/dl, and 53 patients had an Hb level of 11.0 
g/dl or higher. The mean duration of therapy was 3.5 
weeks (7 infusions).
 Patients with severe anemia, treated initially with a 
combination of iron sucrose and rhEPO, showed an im-
mediate response to therapy (group C). The mean Hb lev-
Table 1. Baseline characteristics and pretreatment laboratory characteristics in groups A (iron sucrose), B (iron sucrose + rhEPO after 
2 weeks) and C (iron sucrose + rhEPO from the beginning of therapy) 
Parameter (reference range) Group A (n = 27) Group B (n = 32) Group C (n = 25) p
Gestational age, weeks 31.786.5 (16–39) 28.885.1 (16–37) 28.587.1 (16–41) n.s.
Hb concentration, g/dl (>11.0a) 9.580.3 (9.1–9.9) 9.580.3 (9.0–9.9) 8.380.4 (7.1–8.9) <0.001 A, B vs. C
Hematocrit, % (>33a) 29.381.3 (26.9–32.0) 28.981.5 (26.3–31.9) 26.881.4 (24.8–29.0) <0.001 A, B vs. C
Mean corpuscular volume, fl (80–100) 79.786.8 (66.5–93.0) 82.886.9 (69.2–93.9) 73.186.7 (61.9–88.7) <0.001 A, B vs. C
Mean corpuscular Hb, pg (26–34) 25.882.9 (20.6–31.5) 27.383.0 (21.3–31.5) 22.783.0 (17.8–29.9) <0.001 A, B vs. C
Mean corpuscular Hb concentration, g/dl (31–36) 32.481.2 (29.7–34.0) 32.981.3 (30.6–36.2) 30.981.8 (27.7–33.7) <0.001 A, B vs. C
Reticulocyte count, % (0–1.5) 2.680.9 (1.2–5.6) 2.180.9 (0.5–4.8) 2.381.1 (1.1–5.5) n.s.
Reticulocyte corpuscular Hb, pg (25–28) 27.884.2 (21.5–38.0) 27.283.3 (19.4–33.3) 24.383.5 (18.4–32.8) <0.001 A vs. C
<0.05 B vs. C
Hypochromic red blood cell population, % (<2.5) 9.889.3 (0.4–37.0) 6.888.3 (0.1–32.2) 22.7816.0 (1.0–51.7) <0.001 A, B vs. C
Microcytic red blood cell population, % (<2.5) 7.388.4 (0.4–31.9) 4.987.1 (0.2–30.3) 15.4811.7 (0.9–41.8) <0.05 A vs. C
<0.001 B vs. C
EPO concentration, U/l (<20) 69.3842.8 (21.4–173.0) 46.6829.8 (10.0–138.0) 87.3849.7 (20.0–191.0) <0.05 A vs. B
<0.001 B vs. C
Ferritin concentration, g/l (15–150) 5.482.3 (2.0–12.0) 7.883.7 (3.0–15.0) 6.183.7 (2.0–15.0) <0.05 A vs. B
Transferrin saturation, % (>20) 9.288.2 (2.4–40.1) 11.687.4 (3.3–30.8) 6.386.8 (2.0–32.3) <0.05 B vs. C
sTfR concentration, g/ml (2.2–5.0) 10.284.3 (4.8–20.5) 8.483.3 (2.4–16.1) 3.484.8 (5.9–26.6) <0.05 A vs. C
<0.001 B vs. C
TfR-F index (<3.8) 16.188.7 (5.9–42.9) 10.985.7 (2.4–25.4) 21.5811.5 (5.1–52.9) <0.05 A vs. B, C
<0.001 B vs. C
Vitamin B12 concentration, ng/l (180–900b) 193.2850.3 (90.0–295.0) 243.48132.3 (82.0–710.0) 227.2887.4 (88.0–492.0) n.s.
Red blood cell folate concentration, g/l (>165) 361.48102.9 (165.0–618.0) 332.28164.8 (103.0–800.0) 336.78117.7 (205.0–707.0) n.s.
C–reactive protein concentration, mg/l (<10) 4.582.4 (2.0–9.0) 4.982.5 (2.0–10.0) 3.982.2 (2.0–10.0) n.s.
Data given as mean 8 SD, with ranges in parentheses. a Third trimester reference value. b Reference value for nonpregnant patients.
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el in this group after therapy was 11.2 g/dl ( 8 0.4, range 
10.1–12.6 g/dl). Twenty patients had an Hb level  6 11.0 
g/dl, 5 patients had an Hb level between 10.0 and 10.9
g/dl, of whom 1 patient was not able to complete therapy 
as she gave birth at term after the second infusion.
 Patients with moderate anemia (9.0  ^  Hb  ! 10.0 g/dl; 
groups A and B) were initially treated with iron sucrose 
alone twice weekly. Of the 59 patients, 32 responded 
poorly to therapy according to our protocol (Hb increase 
 ! 0.7 g/dl within 14 days, i.e., after 4 infusions of 200 mg 
iron sucrose) and received additional rhEPO as therapy 
continued.
 In the 27 patients responding well to therapy (group 
A), the mean Hb level after therapy was 11.1 g/dl ( 8 0.4, 
range 10.1–12.0 g/dl) after a mean duration of therapy of 
2.5 weeks (5 infusions).
 The remaining 32 patients (group B) had a mean post-
treatment Hb level of 10.9 g/dl ( 8 0.4, range 10.0–11.7
g/dl) after a mean of 4 weeks of therapy (8 infusions).
 Patients in group A presented statistically significant-
ly higher Hb values compared to patients in group B from 
day 4 until day 22 of therapy (day 4, p = 0.005; day 8, p  ! 
0.0001; day 11, p = 0.003; day 15, p  ! 0.0001; days 18 and 
22, p = 0.005) and also compared to patients in group C 
from day 4 until day 15 (days 4, 8, 11, and 15, p  ! 0.0001). 
Hb value in group B was statistically significantly higher 
on days 4 and 8 compared to group C (day 4, p  ! 0.0001; 
day 8, p  ! 0.005). The course of Hb in all three groups 
during treatment is shown in  figure 1 .
 Those patients identified as poor responders to intra-
venous iron therapy (group B) showed statistically sig-
nificantly lower eEPO levels compared to patients of 
group A who had the same degree of anemia (46.6  8 29.8 
vs. 69.3  8 42.8 U/l; p  ! 0.05). Furthermore, the transfer-
rin receptor-ferritin index (TfR-F index) was statistically 
significantly lower in these patients compared to group A 
(10.9  8 5.7 vs. 16.1  8 8.7; p  ! 0.05). The index is calcu-
lated as sTfR at baseline/log serum ferritin at baseline, 
serving as an established tool for distinguishing iron de-
ficiency anemia from anemia of inflammation. The fer-
ritin level at baseline was also statistically significantly 
higher in those patients compared to group A (7.8  8 3.7 
vs. 5.4  8 2.3   g/l; p  ! 0.05).
 Iron Status 
 Serum ferritin was measured once weekly for monitor-
ing the patients’ iron stores. Overall pretreatment ferritin 
was 6.4   g/l ( 8 3.7, range 2.0–15.0   g/l). At the end of 
therapy, overall ferritin was 184.9   g/l ( 8 95.9, range 
55.0–528.0   g/l). Apart from the above-mentioned dif-
ference at baseline, there was no statistically significant 
difference in all three groups throughout the course of 
therapy, but a tendency to lower ferritin values was ob-
served in those patients treated with rhEPO and iron su-
crose from the beginning of therapy baseline (group C, 
Hb  ! 9.0 g/dl) ( fig. 2 ).
 Transferrin saturation increased from overall baseline 
9.2% ( 8 7.7, range 2.0–40.1%) to overall 19.6% ( 8 8.9, range 
6.1–51.2%) at the end of therapy. At inclusion, transferrin 
saturation was significantly lower in group C compared to 
group B ( table 1 ). There was no statistically significant dif-
ference between the three groups at the end of therapy.
 sTfR was elevated in all three groups at baseline, with 
statistically significantly higher values in group C com-
pared to the other two groups ( table 1 ). This difference 
remained throughout the course of therapy (days 8 and 
15: group C vs. group A, p = 0.001, group C vs. group B, 
p  ! 0.0001; day 22: group C vs. group A, p  ! 0.001, group 
C vs. group B, p  ! 0.001) ( fig. 2 ).
 Hypochromic red cells showed a comparable course, 
with statistically significantly higher values in group C at 
baseline ( table 1 ). Hypochromic red cells remained statis-
tically significantly elevated during therapy in this group 
(days 8, 11 and 15: group C vs. group A and group B, p  ! 
0.0001; day 18: group C vs. group A, p  ! 0.05, group C vs. 
group B, p  ! 0.001; day 22: group C vs. group A, p  ! 0.05, 
group C vs. group B, p = 0.001; day 25: group C vs. group 
B, p  ! 0.05; data available from author upon request).
 eEPO  levels showed a statistically significant differ-
ence as shown in  table 1 . After 1 week of therapy, eEPO 
levels declined but remained elevated until the end of 
therapy (with no statistically significant difference ob-
served between the three groups throughout therapy). 
Overall the mean eEPO level at the end of therapy was 
28.3 U/l ( 8 17.0, range 13.0–90.4 U/l).
 Safety 
 There were no serious adverse events in all three 
groups. No hypotensive responses, allergic reactions, or 
thromboembolic complications were seen during thera-
py. Most patients reported a metallic taste during iron 
sucrose infusion.
 Maternal and Fetal Outcomes 
 Mean gestational age at delivery was 39.7  8 3.1 weeks, 
and mean birth weight was 3,370  8 590 g. There was
no statistically significant difference between all three 
groups. Clinical parameters were normal in all neonates.
 None of the patients needed antepartum or postpar-
tum blood transfusions.
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 Discussion 
 The present study shows an effective treatment regi-
men using iron sucrose alone or in combination with 
rhEPO for patients with various degrees of iron deficien-
cy anemia in pregnancy. It has to be pointed out that all 
patients developed anemia despite routine prescription of 
oral iron supplements (80 mg per day) from the begin-
ning of the second trimester. Patients with severe anemia 
treated with the combination of rhEPO and iron sucrose 
show a rapid response as indicated by the increases in Hb 
and reticulocyte count (data not shown). It is well known 
that rhEPO therapy delivers optimal results when com-
bined with an effective iron substitution to avoid or at 
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least diminish functional iron deficiency. Especially 
when iron stores are empty before therapy, only parenter-
ally administered iron (i.e., iron sucrose) is able to opti-
mize therapy  [12, 13] . In our patients functional iron de-
ficiency was already present at the start of therapy and 
did not worsen during the observation period. Due to the 
fact that in those patients treated with rhEPO and iron 
sucrose functional iron deficiency was still present at the 
end of therapy (shown by elevated hypochromic red cells; 
data available upon request), the question arises whether 
these patients are eligible for oral iron treatment after the 
end of therapy.
 In patients with moderate iron deficiency anemia 
treated with iron sucrose alone we observed variable re-
sponse. One aim of our study protocol was to discrimi-
nate so-called ‘nonresponders’ from patients with mod-
erate anemia who show a good response to intravenous 
iron sucrose. To identify those patients who might ben-
efit from an additional rhEPO therapy, we set a cutoff at 
an Hb increase of  ! 0.7 g/dl after 4 infusions of 200 mg 
iron sucrose each within 14 days. This cutoff was chosen 
on the basis of data on optimal response to oral iron ther-
apy in other clinical settings. With an oral dose of 105 
mg/day optimal Hb increase was given as approximately 
0.1 g/dl/day  [14] . For a conservative anticipation we cut 
this number by half. Those patients receiving additional 
rhEPO in the consecutive therapy sessions (group B) had 
statistically significantly lower rhEPO levels at baseline 
compared to patients of group A who had the same de-
gree of anemia. There are no reference values for eEPO 
levels in pregnancy, but Cazzola et al. [15] suggested that 
eEPO levels  ! 100 U/l are disproportionately low for ane-
mia. Furthermore, there was a statistically significantly 
lower ferritin level in group A compared to group B, al-
though both baseline ferritin mean values were well be-
low 10   g/l. sTfR concentration was not statistically sig-
nificantly different in both groups, but when the sTfR/log 
ferritin ratio was calculated, the so-called nonresponders 
(group B) showed statistically significantly lower values 
compared to the other two groups. The TfR-F index is 
used to distinguish iron deficiency anemia from anemia 
of inflammation and represents a combination of mea-
surements of iron stores (ferritin) and functional tissue 
iron (sTfR)  [16] . In our study population, iron deficiency 
anemia was proven by pathologically low ferritin values. 
A few patients in group B had normal hemoglobinization 
(normal reticulocyte hemoglobin content and normal 
TfR-F index) despite having iron deficiency anemia ac-
cording to their Hb and ferritin levels. One could specu-
late that in a subgroup of our investigated population, 
there exists a form of anemia comparable to anemia of 
inflammation (or anemia of chronic disease), i.e., supple-
mented iron is diverged from the circulation into storage 
sites of the reticuloendothelial system and proliferation 
of erythroid progenitor cells is impaired  [17] . As in our 
patients inflammation/infection was clinically excluded, 
subtle changes in the mechanisms of iron household pos-
sibly influence the success of intravenous iron therapy. As 
hepcidin was identified as the long-sought iron-regula-
tory hormone  [18] , a validated assay in blood or urine of 
those anemic patients would provide a starting point for 
further investigation into the variable efficacy of intrave-
nous iron therapy. Interestingly, only after 2 injections of 
rhEPO did the women in group B (nonresponders) reach 
comparable Hb concentrations as the women in group A 
at the same point of time in therapy. This would support 
the theory of blunted eEPO production (comparable to 
diminished EPO release in anemia of inflammation) in 
the group of the so-called nonresponders.
 It is also conceivable that these patients already prof-
ited from previous oral iron therapy as a lower TfR-F in-
dex reflects lower body iron demand.
 Another explanation might lie in the fact of consider-
able variations in the degree of hemodilution in pregnant 
women. According to a publication of Milman  [19] , the 
Hb concentration may vary up to 3.5 g/dl. It is known that 
Hb as a single parameter is not valid for estimation of the 
iron status. If one has a closer look at the baseline labora-
tory parameters of the patients of the group successfully 
treated with iron alone (group A) and the so-called non-
responders (group B), it is evident that for the same de-
gree of anemia (shown in Hb concentration and hemato-
crit) group B has a statistically significantly higher serum 
ferritin concentration and a statistically significantly 
lower eEPO concentration compared to group A. Mean 
corpuscular volume, mean corpuscular Hb and transfer-
rin saturation also show a tendency towards higher val-
ues, although not statistically significant.
 To date, nonresponders to intravenous iron therapy 
have not been described, but in the study of Bayoumeu et 
al.  [6] , for instance, regarding the increase in Hb, no dif-
ference between orally and intravenously administered 
iron was found. In this study, the total iron sucrose dose 
to be administered was calculated using the formula: 
weight  ! (target Hb – actual Hb)  ! 0.24 + 500 mg, as 
provided by the manufacturer of Venofer  [20] . Unsur-
prisingly, only iron sucrose appeared to restore iron stores 
with a statistically significant difference at any time of 
the treatment period compared to oral iron  [6] . The 
above-mentioned nonresponders to intravenous iron 
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might explain the lack of benefit regarding Hb increase 
of intravenous iron compared to oral iron in the study by 
Bayoumeu et al.  [6] .
 Similar to our experience published in previous stud-
ies  [5, 21] , the safety profile of iron sucrose (Venofer) 
alone or in combination with rhEPO (Eprex) was favor-
able. There were no serious adverse events in all three 
groups. No hypotensive responses, allergic reactions, or 
thromboembolic complications were seen during thera-
py. Most patients reported a metallic taste during iron 
sucrose infusion.
 In conclusion, iron sucrose given intravenously is a 
safe option for the treatment of iron deficiency anemia in 
pregnancy, avoiding well-known side effects of high-dose 
oral iron supplementation, i.e., constipation or abdomi-
nal pain. In cases of severe iron deficiency anemia even a 
combination with rhEPO might be considered, especial-
ly if further risk factors are noted, such as placenta pre-
via, or being a member of Jehovah’s witnesses. If a patient 
is not responding well to therapy with iron sucrose alone, 
additional treatment with rhEPO might be considered.
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